EUVIMEDAtrasti EUVIMED
Crossref

Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization

Pei-Fang Su iD, Chieh-Chi Wu

Statistics in Medicine · 2025

DOI: 10.1002/sim.70149 ↗

At a glance

Journal article in Statistics in Medicine, 2025. Written by Pei-Fang Su and 1 co-authors. Institution: Department of Statistics, National Cheng Kung University, Tainan, Taiwan. Major MEDLINE topics: Randomized Controlled Trials as Topic, Research Design. 28 references. Funded by: National Science and Technology Council.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Estimating the required sample size is an essential task for a clinical trial. It ensures statistical power and makes it possible to draw meaningful conclusions from the study results. Moreover, to minimize treatment imbalances within each covariate subgroup, covariate‐adaptive randomization is a popular method. The first aim of this study is to investigate the required sample size for covariate‐adaptive randomization based on survival outcomes. We evaluate the testing performance using the calculated sample size under simple randomization, stratified permuted block randomization, and covariate‐adaptive biased coin randomization. To provide preliminary insights into the trial's progress and potential efficacy, an interim analysis is commonly conducted. The second aim of the study is to provide a strategy for interim analysis in covariate‐adaptive randomization trials, which involves stopping the trial early based on accumulating data if one treatment arm proves to be significantly more effective or harmful than the others. Because the data collected before and after the interim monitoring time are dependent, performing multiple tests may inflate the overall Type I error rate. We thus re‐estimate the required sample size, propose a valid hypothesis testing method for interim analysis, and study the underlying theoretical properties of the testing statistics, incorporating covariate‐adaptive randomization. The performance of the proposed formula and interim strategy is evaluated through comprehensive simulations, including a sensitivity analysis. We also provide the R code to benefit the readers. Finally, two survival trials, the RE01 trial and a lung cancer study, are treated as pilot studies, and we show that the proposed strategies are valid under covariate‐adaptive randomization.

Subjects

MeSH terms (MEDLINE)

Randomized Controlled Trials as TopicResearch DesignHumansSample SizeSurvival AnalysisComputer SimulationLung NeoplasmsModels, StatisticalData Interpretation, StatisticalRandom Allocation

Author keywords

biased coin randomizationcox modelpowersensitivity analysisstratified permuted block randomizationtype I error rate

Authors and institutions

  • Department of Statistics, National Cheng Kung University, Tainan, Taiwan.

ORCID profiles: Pei-Fang Su

Funding

  • National Science and Technology Council

Cite

APA

Su, P. F., & Wu, C. C. (2025). Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization. Statistics in Medicine. https://doi.org/10.1002/sim.70149

Vancouver

Su PF, Wu CC. Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization. Statistics in Medicine. 2025. doi:10.1002/sim.70149

BibTeX
@article{Su2025,
  author = {Su, Pei-Fang and Wu, Chieh-Chi},
  title = {Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70149}
}
Start for free →